Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Biobank Testis Cancer: Storing Blood for Analysis of Patients With Testis Cancer
This study is currently recruiting participants.
Verified by Maastricht Radiation Oncology, April 2007
Sponsors and Collaborators: Maastricht Radiation Oncology
Maastricht University Medical Center
Information provided by: Maastricht Radiation Oncology
ClinicalTrials.gov Identifier: NCT00181376
  Purpose

The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints which are important for the patient such as overall survival and side effects.


Condition
Testis Cancer

MedlinePlus related topics: Cancer Testicular Cancer Testicular Disorders
U.S. FDA Resources
Study Type: Observational
Study Design: Screening, Longitudinal, Defined Population, Prospective Study
Official Title: Storing Blood for Analysis of DNA and Protein of Patients With Testis Cancer in MAASTRO Clinic

Further study details as provided by Maastricht Radiation Oncology:

Estimated Enrollment: 99
Study Start Date: September 2004
Estimated Study Completion Date: September 2025
Detailed Description:

It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistical strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to draw blood in MAASTRO clinic of all patients with testis cancer and store it encrypted so that we can perform DNA and protein analyses in the future and to correlate the results with survival and toxicity of the treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Testis cancer

Exclusion Criteria:

  • Not able to comply with follow-up
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00181376

Contacts
Contact: Philippe Lambin, Pro PHD +31 (0) 88 44 55 666 philippe.lambin@maastricht.nl
Contact: Dirk De Ruysscher, PHD 031 (0) 88 44 55 666 dirk.deruysscher@maastro.nl

Locations
Netherlands, Limburg
Maastricht Radiation Oncology Recruiting
HEERLEN, Limburg, Netherlands, 6419 PC
Contact: Dirk De Ruysscher, PHD     +31 (0) 88 44 55 666     dirk.deruysscher@maastro.nl    
Contact: Francis Van Gils, PHD     +31 (0) 88 44 55 666     francis.vangils@maastro.nl    
Sponsors and Collaborators
Maastricht Radiation Oncology
Maastricht University Medical Center
Investigators
Principal Investigator: Dirk De Ruysscher, PHD CCMO
  More Information

Study ID Numbers: P03.1150L
Study First Received: September 12, 2005
Last Updated: April 24, 2007
ClinicalTrials.gov Identifier: NCT00181376  
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht Radiation Oncology:
testis cancer,
genomics,
proteomics

Study placed in the following topic categories:
Genital Neoplasms, Male
Gonadal Disorders
Testicular Diseases
Endocrine System Diseases
Testicular cancer
Urogenital Neoplasms
Endocrinopathy
Testicular Neoplasms
Genital Diseases, Male
Endocrine Gland Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 16, 2009